14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
MBIO vs SRZN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Surrozen, Inc. Common (SRZN) is the stronger overall head-to-head candidate over Mustang Bio, Inc. (MBIO) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). MBIO carries a Unified Composite Score of 42.9/100 (HOLD) at $0.39 (N/M Forward P/E, 0.0% operating margin), whereas SRZN carries 33.2/100 (SELL) at $32.32 (N/M Forward P/E, -485.4% operating margin).
Composite vs. Pillar Nuance: While MBIO currently prints a higher short-term Unified Composite Score (42.9/100 HOLD vs. SRZN 33.2/100 SELL), SRZN captures the overall institutional head-to-head verdict (4–3 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-485.4% vs. 0.0% operating margin) and revenue trajectory (+408.6% vs. +0.0% YoY).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MBIO vs SRZN. Trailing 12-month operating profitability (MBIO 0.0% vs SRZN -485.4%) and valuation multiples (MBIO N/M vs SRZN N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $602.5M market capitalization and -485.4% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ MBIO vs SRZN Key Questions & Quantitative Answers
As of Nov 16, 2026, Surrozen, Inc. Common (SRZN) is the stronger overall head-to-head candidate over Mustang Bio, Inc. (MBIO) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). MBIO carries a Unified Composite Score of 42.9/100 (HOLD) at $0.39 (N/M Forward P/E, 0.0% operating margin), whereas SRZN carries 33.2/100 (SELL) at $32.32 (N/M Forward P/E, -485.4% operating margin). Composite vs. Pillar Nuance: While MBIO currently prints a higher short-term Unified Composite Score (42.9/100 HOLD vs. SRZN 33.2/100 SELL), SRZN captures the overall institutional head-to-head verdict (4–3 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-485.4% vs. 0.0% operating margin) and revenue trajectory (+408.6% vs. +0.0% YoY).
SRZN leads the Growth & Scale pillar: MBIO posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with SRZN at +408.6% YoY revenue growth and -37.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, -485.4% operating margin). On trailing 12-month operating scale, MBIO generates N/A in USD-normalized revenue versus $11M for SRZN. In operating R&D and SG&A reinvestment, MBIO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SRZN.
SRZN screens cheaper on headline valuation multiples. MBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas SRZN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 48.3x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MBIO (-43.1% ROE) versus SRZN (-62.8% ROE) capital efficiency.
In options market volatility and institutional positioning, MBIO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.66β · 86% Vol realized risk). By comparison, SRZN carries 72.0% implied volatility (5th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.21β · 62% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.